Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Cynthia Pussinen as Chief Executive Officer and Chairperson of its Board of Directors, effective October 25, 2026. Ms. Pussinen succeeds Cheng Liu, Ph.D., as Chief Executive Officer. Dr. Liu has been appointed Chief Scientific Officer and will continue to serve as the Company's President and as a member of the Board of Directors.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.